Literature DB >> 17578790

Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.

Jean-Jacques Parienti1, Veronique Massari, David Rey, Patrice Poubeau, Renaud Verdon.   

Abstract

Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17578790     DOI： 10.1086/518973

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

Review 1.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

2.  Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.

Authors:  Leigh Anne Redhage; Ayumi Shintani; David W Haas; Nkiruka Emeagwali; Milica Markovic; Ikwo Oboho; Christopher Mwenya; Husamettin Erdem; Edward P Acosta; Jason D Morrow; Todd Hulgan
Journal:  HIV Clin Trials       Date:  2009 May-Jun

3.  Switching antiretroviral therapy to minimize metabolic complications.

Authors:  Jordan E Lake; Judith S Currier
Journal:  HIV Ther       Date:  2010-11

4.  WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.

Authors:  Deborah Cohan; Julia Mwesigwa; Paul Natureeba; Flavia Aliba Luwedde; Veronica Ades; Albert Plenty; Abel Kakuru; Jane Achan; Tamara Clark; Beth Osterbauer; Moses Kamya; Diane Havlir
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

5.  Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells.

Authors:  Md Saha Jamaluddin; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Atherosclerosis       Date:  2009-07-23       Impact factor: 5.162

6.  Effects of PPARγ and RBP4 gene variants on metabolic syndrome in HIV-infected patients with anti-retroviral therapy.

Authors:  Yuan-Pin Hung; Nan-Yao Lee; Sheng-Hsiang Lin; Ho-Ching Chang; Chi-Jung Wu; Chia-Ming Chang; Po-Lin Chen; Hsiao-Ju Lin; Yi-Hui Wu; Pei-Jane Tsai; Yau-Sheng Tsai; Wen-Chien Ko
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

7.  Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

Authors:  Sara Melzi; Laura Carenzi; Maria Vittoria Cossu; Simone Passerini; Amedeo Capetti; Giuliano Rizzardini
Journal:  Cholesterol       Date:  2010-10-31

8.  Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.

Authors:  Josep M Llibre; Isabel Bravo; Arelly Ornelas; José R Santos; Jordi Puig; Raquel Martin-Iguacel; Roger Paredes; Bonaventura Clotet
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

9.  Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Authors:  Mutsawashe Bwakura-Dangarembizi; Victor Musiime; Alexander J Szubert; Andrew J Prendergast; Zvenyika A Gomo; Margaret J Thomason; Cuthbert Musarurwa; Peter Mugyenyi; Patricia Nahirya; Adeodata Kekitiinwa; Diana M Gibb; Ann S Walker; Kusum Nathoo
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

10.  Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: characteristics and independent risk factors.

Authors:  Jiang Xiao; Ning Han; Di Yang; Hongxin Zhao
Journal:  Virol J       Date:  2013-08-14       Impact factor: 4.099
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.